Nehra A
Department of Urology, Mayo Medical School, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.
Curr Urol Rep. 2001 Dec;2(6):468-72. doi: 10.1007/s11934-001-0041-9.
Erectile dysfunction is a common problem in men older than 40 years, and the incidence increases markedly with age. Approximately one fourth of impotent men use intracavernosal injections as a primary treatment. Since its original description in the early 1980s, injection therapy has been used safely and successfully by many men and their partners. Intraurethral and oral agents for the treatment of erectile dysfunction have been introduced over the last few years, but early reports of patient satisfaction and reproducibility of erectile rigidity have not matched those of intracavernosal therapy. Thus, injection therapy remains on the forefront of treatment options.
勃起功能障碍是40岁以上男性的常见问题,且发病率随年龄显著增加。约四分之一的阳痿男性将海绵体内注射作为主要治疗方法。自20世纪80年代初首次描述以来,许多男性及其伴侣已安全、成功地使用了注射疗法。在过去几年中,已推出用于治疗勃起功能障碍的尿道内用药和口服药物,但关于患者满意度和勃起硬度可重复性的早期报告不如海绵体内治疗。因此,注射疗法仍处于治疗选择的前沿。